TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6368753

Group type: EXPERIMENTAL
Intervention: Rectal administration of diazepam 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of diazepam 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30885262

Group type: EXPERIMENTAL
Intervention: Arterial blood gas analysis (ABG)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard care (noABG)
Number of subjects: 310
Study: 30367238

Group type: EXPERIMENTAL
Intervention: Purse-string approximation (PSA)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Primary closure with a drain (PCD)
Number of subjects: 159
Study: 28499930

Group type: EXPERIMENTAL
Intervention: High working memory capacity with low attentional bias to food cues
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low working memory capacity with high attentional bias to food cues
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High working memory capacity with maintained attention to food cues
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low working memory capacity with maintained attention to food cues
Number of subjects: 96
Study: 25427598

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg IV)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Thiopental (4 mg/kg IV)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/kg IV)
Number of subjects: 45
Study: 24227734

Group type: EXPERIMENTAL
Intervention: Responses to body effectors (e.g., hands, feet, limbs) in lateral occipitotemporal cortex (LOTC) and parietal cortex.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hand-selective region in left LOTC responding to object effectors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-brain representational similarity analysis.
Number of subjects: 0
Study: 21848497

Group type: EXPERIMENTAL
Intervention: Low-dose transdermal estradiol (E2) gel (0.9 g/day, containing E2 0.54 mg/day)
Number of subjects: 209

Group type: COMPARATOR
Intervention: E2-free placebo
Number of subjects: 209
Study: 19214559

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Treatment-related factors
Number of subjects: 121

Group type: COMPARATOR
Intervention: Socio-economic and demographic characteristics
Number of subjects: 121
Study: 17166576

Group type: EXPERIMENTAL
Intervention: Metaphor explanation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-metaphorical meanings
Number of subjects: 20
Study: 15159191

Group type: EXPERIMENTAL
Intervention: Verification condition (idiom comprehension test)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Story condition (idiom comprehension test)
Number of subjects: 22

Group type: COMPARATOR
Intervention: High and moderate familiarity idioms in verification condition
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low familiarity idioms in story condition
Number of subjects: 22
Study: 11869171

Group type: EXPERIMENTAL
Intervention: Glibenclamide (10 mg day-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acarbose (300 mg day-1)
Number of subjects: 12
Study: 9602197

Group type: EXPERIMENTAL
Intervention: Standard physical activity and nutrition program with physical activity enrichment for higher risk children
Number of subjects: 800

Group type: COMPARATOR
Intervention: No program (control schools)
Number of subjects: 800
Study: 8041850

Group type: EXPERIMENTAL
Intervention: Direct mail with named address
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Direct mail with bulk rate postage
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Direct mail with first class postage
Number of subjects: 1000
Study: 2738909

Group type: EXPERIMENTAL
Intervention: Alpha-gliadin antibodies (AGA) of subclasses IgG1 and IgG3 in coeliac patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IgG3 AGA levels in coeliac group
Number of subjects: 0

Group type: COMPARATOR
Intervention: IgG4 titres in control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-gliadin-specific complement fixation in coeliac patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alpha-gliadin-specific complement fixation matched for total IgG AGA
Number of subjects: 0
Study: 29278929

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg orally (PO)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg PO
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 28410886

Group type: EXPERIMENTAL
Intervention: Sternoclavicular grafts (SCG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Transport distraction osteogenesis (TDO)
Number of subjects: 22
Study: 26278649

Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: enzalutamide
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High subcutaneous adipose tissue (SAT) index
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Skeletal muscle mass (SMM) index
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Visceral metastasis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SAT index
Number of subjects: 120
Study: 23642944

Group type: EXPERIMENTAL
Intervention: Turkish classical music
Number of subjects: 60

Group type: COMPARATOR
Intervention: Resting period (control group)
Number of subjects: 60
Study: 21565322

Group type: EXPERIMENTAL
Intervention: Immunonephelometric assay (INA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-high-density lipoprotein cholesterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vertical auto profile (VAP)
Number of subjects: 0
Study: 19243778

Group type: EXPERIMENTAL
Intervention: 40 min, one-on-one education and counseling session
Number of subjects: 3522

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3522
Study: 17046320

Group type: EXPERIMENTAL
Intervention: HSV-1 shedding
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HSV-1 peak viral load
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HSV-1 detection
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HSV-2 detection
Number of subjects: 22
Study: 15744697

Group type: EXPERIMENTAL
Intervention: Osteogenic Protein-1 (OP-1) with intramedullary rod fixation
Number of subjects: 122

Group type: COMPARATOR
Intervention: Fresh autogenous bone graft with intramedullary rod fixation
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Osteogenic Protein-1 (OP-1)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Fresh autogenous bone graft
Number of subjects: 122
Study: 11252646

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9263186

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mineral group: 20 mg zinc, 100 micrograms selenium
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vitamin group: 120 mg vitamin C, 6 mg beta‐carotene, 15 mg vitamin E
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mineral and vitamin group: Zn 20 mg, Se 100 micrograms, Vit C 120 mg, beta CA 6 mg, Vit E 15 mg
Number of subjects: 81
Study: 8470850

Group type: EXPERIMENTAL
Intervention: ICU admissions
Number of subjects: 16622
Study: 6924693

Group type: EXPERIMENTAL
Intervention: Demand feeding (N = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Scheduled feeding (N = 18)
Number of subjects: 36
Study: 31539371

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 60
Study: 27931053

Group type: EXPERIMENTAL
Intervention: Blood Flow Restricted Resistance Exercise (BFR‐RE) at 30% of 1-RM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Exercise (HI‐RE) at 80% of 1-RM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-Intensity Resistance Exercise (LI‐RE) at 30% of 1-RM
Number of subjects: 12
Study: 24961993

Group type: EXPERIMENTAL
Intervention: Technology-assisted balance and gait training (BAL)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Strengthening exercises (CON)
Number of subjects: 51
Study: 23376475

Group type: EXPERIMENTAL
Intervention: Young adults (23-25 years old)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Late adolescents (18-19 years old)
Number of subjects: 74
Study: 21548978

Group type: EXPERIMENTAL
Intervention: Flexible nasendoscope with gel cap
Number of subjects: 35

Group type: COMPARATOR
Intervention: Flexible nasendoscope without gel cap (control)
Number of subjects: 35
Study: 19399262

Group type: EXPERIMENTAL
Intervention: CCB plus ACEI (group II)
Number of subjects: 87

Group type: COMPARATOR
Intervention: CCB (group I)
Number of subjects: 87
Study: 17708625

Group type: EXPERIMENTAL
Intervention: Rhubarb treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 16787193

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day) for 7 days
Number of subjects: 0
Study: 12672280

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) assessment
Number of subjects: 56
Study: 10448024

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study: 7742052

Group type: EXPERIMENTAL
Intervention: Prophylactic somatostatin (4.5 mg daily in continuous perfusion for 7 days postoperatively)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no somatostatin)
Number of subjects: 35
Study: 2048370

Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 661
Study: 6752929

Group type: EXPERIMENTAL
Intervention: Bamifylline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 16
Study: 31657637

Group type: EXPERIMENTAL
Intervention: 750-g ice bag applied for 10 to 60 minutes based on subcutaneous adipose thickness
Number of subjects: 14
Study: 28178599

Group type: EXPERIMENTAL
Intervention: Dexpramipexole (50mg to 300mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25367403

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cancer recovery (MBCR)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (SET)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combined intervention group (MBCR and SET)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Minimal intervention control (1-day stress management seminar)
Number of subjects: 88
Study: 22692106

Group type: EXPERIMENTAL
Intervention: Fast Force Endurance (FFE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maximum Strength (MAX)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Strength Endurance (SE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypertrophy (HYP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: All RTMs
Number of subjects: 10
Study: 21748907

Group type: EXPERIMENTAL
Intervention: A-50 condition (50% alignment to gravito-inertial force)
Number of subjects: 12

Group type: COMPARATOR
Intervention: A-0 condition (0% alignment to gravito-inertial force)
Number of subjects: 12

Group type: COMPARATOR
Intervention: A-100 condition (100% alignment to gravito-inertial force)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 12
Study: 18071079

Group type: EXPERIMENTAL
Intervention: Quinapril, target dose 40 mg/d
Number of subjects: 2553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2553
Study: 16521091

Group type: EXPERIMENTAL
Intervention: MR elastography
Number of subjects: 25
Study: 12672922

Group type: EXPERIMENTAL
Intervention: Sprinkles containing 80 mg iron and 10 mg zinc (FeZn)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Sprinkles containing 80 mg iron (Fe)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Both groups (Fe and FeZn)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: FeZn group
Number of subjects: 304

Group type: COMPARATOR
Intervention: Fe group
Number of subjects: 304
Study: 11099367

Group type: EXPERIMENTAL
Intervention: Active Recovery (AR) - 15 min running at 50% of VáO2max
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rest Recovery (RR) - complete rest in the supine position
Number of subjects: 14
Study: 8729205

Group type: EXPERIMENTAL
Intervention: Clemastine fumarate (1.34 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 1585845

Group type: EXPERIMENTAL
Intervention: Exercise-Meal (25 min cycle at 60% VO2 max followed by a 902 kcal mixed meal)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Meal-Exercise (902 kcal mixed meal followed by 25 min cycle at 60% VO2 max)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Meal Only (902 kcal mixed meal)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Resting Control
Number of subjects: 6

Group type: COMPARATOR
Intervention: Exercise Only (25 min cycle at 60% VO2 max)
Number of subjects: 6
Study: 6086772

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30808743

Group type: EXPERIMENTAL
Intervention: Monitor+Accept
Number of subjects: 153

Group type: COMPARATOR
Intervention: Monitor Only
Number of subjects: 153

Group type: COMPARATOR
Intervention: Active control training
Number of subjects: 153
Study: 30538086

Group type: EXPERIMENTAL
Intervention: Continuous remote monitoring
Number of subjects: 226

Group type: COMPARATOR
Intervention: Intermittent monitoring alone
Number of subjects: 226
Study: 26984569

Group type: EXPERIMENTAL
Intervention: 12-month physical exercise program, 40 minutes twice weekly for 1 year
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 12-month physical exercise program
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (usual daily activities)
Number of subjects: 78
Study: 24567651

Group type: COMPARATOR
Intervention: Rosemary Conley
Number of subjects: 3290

Group type: COMPARATOR
Intervention: Slimming World
Number of subjects: 3290

Group type: COMPARATOR
Intervention: NHS group programme
Number of subjects: 3290

Group type: EXPERIMENTAL
Intervention: Weight Watchers
Number of subjects: 3290
Study: 22025490

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion with ropivacaine 2 mg/mL at 5 mL/h for 48 hours
Number of subjects: 58

Group type: COMPARATOR
Intervention: Epidural morphine 2 mg every 12 hours for 48 hours
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion with ropivacaine
Number of subjects: 58
Study: 20811292

Group type: EXPERIMENTAL
Intervention: TT homozygotes of rs2006765
Number of subjects: 1998

Group type: COMPARATOR
Intervention: CC+CT genotype of rs2006765
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: SNP rs4681443 of AGTR1 gene
Number of subjects: 1998
Study: 18642564

Group type: EXPERIMENTAL
Intervention: Cytotec (Misoprostol) oral application (50 microg every 4 hours, max 200 microg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cytotec (Misoprostol) vaginal application (two doses of 50 microg every 6 hours)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cytotec (Misoprostol) sub-lingual application (50 microg every 4 hours)
Number of subjects: 45

Group type: COMPARATOR
Intervention: General population frequency of Sectio Caesarea
Number of subjects: 45
Study: 16232069

Group type: EXPERIMENTAL
Intervention: Enhanced version of the Incredible Years Series (n = 50)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No-intervention control condition (n = 49)
Number of subjects: 99
Study: 11157568

Group type: EXPERIMENTAL
Intervention: Patients with torticollis spasmodicus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 9598451

Group type: EXPERIMENTAL
Intervention: Triple combination (1.07 mg/kg mefloquine, 2.14 mg/kg sulfadoxine, 0.11 mg/kg pyrimethamine)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (2.14 mg/kg sulfadoxine, 0.11 mg/kg pyrimethamine)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Mefloquine alone (1.07 mg/kg)
Number of subjects: 231
Study: 7930430

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 20
Study: 3280128

Group type: EXPERIMENTAL
Intervention: Biperiden (5.0 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clonazepam (1.0 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lisuride (0.05 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31608676

Group type: EXPERIMENTAL
Intervention: Work-directed rehabilitation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 42
Study: 30585267

Group type: EXPERIMENTAL
Intervention: Limb ischemic post-conditioning (LIPOC)
Number of subjects: 16
Study: 28533148

Group type: EXPERIMENTAL
Intervention: High-frequency (20Hz) rTMS applied to the right dorsal lateral prefrontal cortex (DLPFC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SHAM treatment
Number of subjects: 40
Study: 25829103

Group type: EXPERIMENTAL
Intervention: Psycho-education combined with pharmacotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine counselling (Control)
Number of subjects: 80
Study: 24134449

Group type: EXPERIMENTAL
Intervention: Nevirapine based ART
Number of subjects: 135

Group type: COMPARATOR
Intervention: Efavirenz based ART
Number of subjects: 135
Study: 21138825

Group type: EXPERIMENTAL
Intervention: Exenatide, 10 µg twice daily for 30 weeks
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo for 30 weeks
Number of subjects: 261
Study: 18822845

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy with antihypertensive drugs
Number of subjects: 0
Study: 16847290

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg, uptitrated to 15 mg if necessary)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 498
Study: 12704354

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1025
Study: 10320243

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (group MP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous placebo (group NS)
Number of subjects: 0
Study: 9005421

Group type: EXPERIMENTAL
Intervention: Active acromegaly (group A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal glucose tolerance (group AT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Impaired glucose tolerance (group AN)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls (group K)
Number of subjects: 22
Study: 1924643

Group type: EXPERIMENTAL
Intervention: Nicotine (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined effects of scopolamine and nicotine
Number of subjects: 0
Study: 6354318

Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Finger temperature feedback
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: EMG plus finger temperature feedback
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 63
Study: 30342296

Group type: EXPERIMENTAL
Intervention: East cohort (DES)
Number of subjects: 6503

Group type: COMPARATOR
Intervention: West cohort (DES)
Number of subjects: 6503
Study: 27426024

Group type: EXPERIMENTAL
Intervention: Yoga training (60-min classes weekly for six months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 12
Study: 24247413

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask (LM) method
Number of subjects: 140

Group type: COMPARATOR
Intervention: Endotracheal (ET) method
Number of subjects: 140
Study: 22637363

Group type: EXPERIMENTAL
Intervention: Cycling group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 20565215

Group type: EXPERIMENTAL
Intervention: Reassignment of arbitrary cue-target pairings midway through the experiment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control for effects of order of conditions or simple change of cue meaning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Re-pairing members of the same cue and target sets
Number of subjects: 0
Study: 18992139

Group type: EXPERIMENTAL
Intervention: Experimental management arm
Number of subjects: 3000

Group type: COMPARATOR
Intervention: EQ-5D health state classification
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Independent measure of distress
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Changes in EQ-5D severities
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Subject's perceived locus of control
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Age, educational attainment, ethnic origin, smoking behaviour
Number of subjects: 3000
Study: 15969863

Group type: EXPERIMENTAL
Intervention: Epoetin alfa treatment
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Pre-treatment erythropoietin levels
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Early response variables (change in haemoglobin after 4 weeks)
Number of subjects: 1010
Study: 12870985

Group type: EXPERIMENTAL
Intervention: Ferric sulphate (FS) 15.5% solution applied for 15 seconds
Number of subjects: 70

Group type: COMPARATOR
Intervention: Formocresol (FC) full strength (Buckley's formula) applied for 5 minutes
Number of subjects: 70
Study: 10529851

Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE) analgesia
Number of subjects: 110
Study: 7663659

Group type: EXPERIMENTAL
Intervention: rhDNase once daily
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: rhDNase twice daily
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968